Fig. 1 · Structure

Documents & Downloads

SF2523

Cat. No. A20557 CAS 1174428-47-7

PI3K inhibitor

SF2523 is a highly selective and potent inhibitor of PI3K with IC50s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.

In Stock

Publications for SF2523

1 publication citing this product

  1. Virender Kumar, .et al. , Biomaterials, 2021, Nov;278:121138 PMID: 34634662

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SF2523 is a dual PI3K–BRD4 research inhibitor. Cell-free experiments support BRD4 binding and inhibition of acetylated histone-peptide recognition, with stronger activity toward BD1 than BD2. Binding also extends to BRD2 and BRD3. Cellular experiments link SF2523 treatment to reduced AKT phosphorylation and displacement of BRD4 from the MYCN promoter. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PI3Kα IC50 34 nM
PI3Kγ IC50 158 nM
BRD4 (BD1) IC50 241 nM
DNA-PK IC50 9 nM
mTOR IC50 280 nM

Cellular Effect

Cell Line Activity Value Description Reference
786-0 IC50 3.3 μM Inhibition of human 786-O cell proliferation after 72 hrs by spectrophotometric analysis [PMID: 23410005]
BT-474 IC50 3.8 μM Inhibition of human BT474 cell proliferation after 72 hrs by spectrophotometric analysis [PMID: 23410005]
NCI-H1299 IC50 0.9 μM Inhibition of human H1299 cell proliferation after 72 hrs by spectrophotometric analysis [PMID: 23410005]
PC-3 IC50 1.6 μM Inhibition of human PC3 cell proliferation after 72 hrs by spectrophotometric analysis [PMID: 23410005]

SF2523 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of SF2523 from 1 published reference.

SF2523 In Vitro Studies

In MYCN-amplified SKNBE2 neuroblastoma cells, SF2523 reduced MYCN mRNA and MYCN/Cyclin D1 protein while inhibiting AKT Ser473 phosphorylation. JQ1 reduced MYCN-related readouts without reducing pAKT, whereas CAL101 did not displace BRD4 from the MYCN promoter. RNA/protein assays and promoter-occupancy assays used different SF2523 concentrations and timings. [1]

Cell-free BRD4 binding and histone-peptide displacement

Biochemical assay · BRD4 full-length protein and isolated BRD4 BD1/BD2; comparator bromodomains and PI3Kα enzyme assay [1]

SF2523 bound BRD4 and displaced acetylated histone peptide. BD1 affinity exceeded BD2 affinity, and binding also extended to BRD2/BRD3. The enzyme-assay table independently identifies PI3Kα inhibition; no PI3K potency number is adopted because a sentence in the Results ambiguously assigns the 16 nM value.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SF2523 binding to full-length BRD4Kd 140 nM[1]
SF2523 binding to BRD4 BD1Kd 150 nM[1]
SF2523 binding to BRD4 BD2Kd 710 nM[1]
Displacement of tetra-acetylated histone H4 peptide from BRD4 BD1IC50 241 nM[1]
Displacement of tetra-acetylated histone H4 peptide from BRD4 BD2IC50 1,550 nM[1]

Literature-Reported Treatment Conditions

Method
Cell-free binding and displacement assays; separate PI3K ADAPTA enzyme assay.
Reported limits
Main text does not provide all commercial-assay incubation and solvent conditions. Kd and IC50 are assay endpoints, not cell-treatment concentrations.
Methods and source locations

Compound reported in the paper: SF2523; Compound label in the paper: SF2523

Applies to the research compound SF2523, without supplier-lot equivalence or clinical efficacy claims.

Figures 1D and 2A–B; Results: BDs Are Targets of TP-Scaffold Inhibitors; Methods: Tissue Culture, Cell Lines, and Reagents; Binding and Displacement Assays and Kinase Screening

SF2523 binding to full-length BRD4: BROMOscan binding assay — Figure 1D; Results: BDs Are Targets of TP-Scaffold Inhibitors; Methods: Binding and Displacement Assays and Kinase Screening

SF2523 binding to BRD4 BD1: BROMOscan binding assay — Figure 1D

SF2523 binding to BRD4 BD2: BROMOscan binding assay — Figure 1D

Displacement of tetra-acetylated histone H4 peptide from BRD4 BD1: AlphaScreen displacement assay using His-tagged bromodomains and H4K5ac/8ac/12ac/16ac-Biotin — Figure 2A–B; Methods: Binding and Displacement Assays and Kinase Screening

Displacement of tetra-acetylated histone H4 peptide from BRD4 BD2: AlphaScreen histone-peptide displacement assay — Figure 2A–B

Dual-pathway responses in MYCN-amplified neuroblastoma cells

Cell-based study · Human SKNBE2 neuroblastoma cells; IGF-stimulated signaling and MYCN-promoter ChIP assays [1]

SF2523 reduced MYCN transcript and MYCN/Cyclin D1 protein and inhibited AKT Ser473 phosphorylation. In the linked promoter-occupancy experiment, SF2523 displaced BRD4 at both tested MYCN promoter regions. JQ1 reduced MYCN-related readouts without inhibiting pAKT; CAL101 did not displace BRD4. These are pathway-response and promoter-occupancy data, not direct MYCN binding or a cell-viability IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MYCN mRNA relative to DMSO controlrelative expression Approximately sevenfold reduction (author-reported approximation)[1]
MYCN, Cyclin D1 and AKT Ser473 phosphorylationqualitative immunoblot response Decreased MYCN and Cyclin D1; reduced pAKT[1]
BRD4 occupancy at MYCN promoter R-1 and R-2ChIP enrichment Decreased occupancy at both promoter regions[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM SF2523 for RT-PCR and Western blotting; 2 μM SF2523 for ChIP.
Exposure duration
24 h for RT-PCR and ChIP; 30 min for Western blotting.
Method
For RNA/protein assays, 4 h serum starvation followed by 50 ng/mL IGF stimulation and inhibitor treatment. ChIP used its separately reported conditions.
Vehicle
DMSO control for Figure 1A; no-inhibitor, anti-BRD4 and rabbit-IgG controls in ChIP.
Co-treatment
SF2523 alone. Separate comparator arms: JQ1, SF1126, BKM120, BEZ235 and CAL101; not a combined-drug treatment.
Reported limits
Figure 1A does not specify replicate count in its caption. Figure 1C specifies triplicate experiments. ChIP concentration differs from RNA/protein assays and is retained separately.
Methods and source locations

Compound reported in the paper: SF2523; Compound label in the paper: SF2523

Applies to the research compound SF2523, without supplier-lot equivalence or clinical efficacy claims.

Figure 1A–C; Results: Morpholinothienopyrane Is a Dual Inhibitor of PI3K and BRD4; Methods: Tissue Culture, Cell Lines, and Reagents; Western Blotting; RNA Extraction and RT-PCR; ChIP

MYCN mRNA relative to DMSO control: RT-PCR normalized to GAPDH — Figure 1A; Results: Morpholinothienopyrane Is a Dual Inhibitor of PI3K and BRD4; Methods: RNA Extraction and RT-PCR

MYCN, Cyclin D1 and AKT Ser473 phosphorylation: Western blotting with total AKT and β-actin controls — Figure 1B; Methods: Western Blotting

BRD4 occupancy at MYCN promoter R-1 and R-2: BRD4 ChIP-qPCR; input normalization, rabbit IgG and a MYCN negative-control region; ±SEM from triplicate experiments — Figure 1C; Methods: ChIP

SF2523 In Vivo Studies

In a subcutaneous SKNBE2 xenograft experiment in immunocompromised mice, SF2523 monotherapy at 50 mg/kg intraperitoneally three times weekly reduced tumor growth relative to vehicle. Body weight showed no notable treatment-associated change, a limited tolerability observation. The article inconsistently identifies the mouse strain as nude and NSG; no strain-specific conclusion is drawn. [1]

SF2523 monotherapy in SKNBE2 subcutaneous xenografts

Animal study · SKNBE2 subcutaneous xenografts in immunocompromised female mice; precise strain unresolved because Methods describes mice as both nude and NSG. [1]

SF2523 monotherapy reduced tumor growth relative to vehicle. Body weight showed no notable treatment-associated change over the experiment. This limited tolerability readout does not establish general safety. Tumor RNA/protein analyses from the same experiment supported reduced MYCN/Cyclin D1 and pAKT.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SKNBE2 xenograft tumor volumequalitative treatment effect Reduced tumor growth versus vehicle[1]
Mouse body weight during SF2523 treatmentqualitative tolerability observation No notable change in body weight attributed to treatment[1]
MYCN/Cyclin D1 transcripts and MYCN/Cyclin D1/pAKT protein in harvested tumorsqualitative molecular response Reduced transcript and protein readouts versus vehicle[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Three times a week
Treatment course
From tumor volume ~100 mm³ (~30 days after implantation) until tumor harvest; exact fixed course not stated in protocol text.
Vehicle
DMSO vehicle is identified for the control; treated formulation composition is not separately detailed.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SF2523 monotherapy
50 mg/kg
Vehicle (DMSO); n = 6 animals per experimental group.Tumor growth reduced relative to vehicle, with no notable body-weight change; tumor MYCN/Cyclin D1 and pAKT readouts decreased.[1]
SF2523 monotherapy
Model: SKNBE2 subcutaneous xenografts in immunocompromised female mice; precise strain unresolved because Methods describes mice as both nude and NSG.
Reported limits: Precise mouse strain unresolved from nude/NSG wording; no fixed dose count inferred.
Methods and source locations

Compound reported in the paper: SF2523; Compound label in the paper: SF2523

Applies to the research compound SF2523, without supplier-lot equivalence or clinical efficacy claims.

Figure 5A–E and caption; Results: TP Inhibitor Blocks Tumor Growth, Metastasis, and PI3K/BRD4 Signaling in Vivo; Methods: In Vivo Tumor Growth and Metastasis Experiments

SKNBE2 xenograft tumor volume: Serial tumor measurements; volume = (length × width²)/2; n = 6 animals per experimental group — Figure 5A and caption; Results: TP Inhibitor Blocks Tumor Growth, Metastasis, and PI3K/BRD4 Signaling in Vivo; Methods: In Vivo Tumor Growth and Metastasis Experiments

Mouse body weight during SF2523 treatment: Serial body-weight measurements; no exact values inferred from curves — Figure 5B and caption; corresponding Results

MYCN/Cyclin D1 transcripts and MYCN/Cyclin D1/pAKT protein in harvested tumors: RT-PCR and Western blotting; tumor harvest 4 h after final treatment; protein signals normalized to β-actin — Figure 5C–E and caption; corresponding Results

SF2523 monotherapy · Figure 5A–E and caption; Methods: In Vivo Tumor Growth and Metastasis Experiments

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1174428-47-7
Applications PI3K inhibitor
Formula C19H17NO5S
Molecular Weight 371.41
SMILES
O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC=C(OCCO5)C5=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 29 mg/mL (78.08 mM)
Water Insoluble
Ethanol 7 mg/mL (18.84 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SF2523 Research References

  1. [1] Forest H Andrews, Alok R Singh, Shweta Joshi, et al. Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis Proceedings of the National Academy of Sciences of the United States of America (2017). PMID: 28137841 DOI: 10.1073/pnas.1613091114 Source material

Publications

1 publication citing this product

  1. Virender Kumar, .et al. , Biomaterials, 2021, Nov;278:121138 PMID: 34634662

Added to your cart

View Cart Checkout
Loading...